Navigation Links
Alzheimer's Research Spotlights Protein 'Tangles' in Brain
Date:7/13/2010

By Amanda Gardner
HealthDay Reporter

TUESDAY, July 13 (HealthDay News) -- Several new studies to be presented Tuesday at a major Alzheimer's conference describe progress in a series of immune-based therapies that target the tau protein, one of the two major proteins implicated in Alzheimer's disease.

As a focus of research, tau protein "tangles" have typically taken a backseat to another protein, the beta amyloid plaques that proliferate in the brains of people with Alzheimer's.

However, the new studies suggest that not only do some tau-focused therapies show promise, some treatments targeted against beta amyloid also affect tau.

William Thies, chief medical and scientific officer at the Alzheimer's Association, called the new results "encouraging."

"These are two landmark lesions associated with Alzheimer's. We had thought that affecting one would affect the other," he said. "This suggests we're getting at the heart of the science, though we still have to show that [these approaches] reduce symptoms."

But another expert added a note of caution.

Dr. Gary Kennedy, director of geriatric psychiatry at Montefiore Medical Center in New York City, said that although attempts to battle beta amyloid and tau might yield treatment results down the line, both deposits "may be manifestations of the disease and not its origin." That comes back to a basic science question plaguing the Alzheimer's field: Do these protein accumulations actually cause Alzheimer's, or are they merely a result of another process?

Also, only one of the studies presented at the meeting was conducted in humans and only 10 humans at that -- meaning that the results should be considered very preliminary.

Still, scientists continue to unravel the mystery of Alzheimer's and what it does to the brain. There are currently no curative treatments for this form of dementia, which affects millions of people worldwide.

The findings, from American and international teams of researchers, are slated for presentation at the Alzheimer's Association's International Conference on Alzheimer's Disease 2010 in Honolulu.

Two studies presented together found that treatments aimed at beta amyloid plaques might also tackle tau.

In one study, an antibody known as bapineuzumab -- which actually aims for beta amyloid plaques -- also reduced levels of an abnormal form of tau known as phospho-tau (P-tau) in spinal fluid. The study authors reported ties with drug makers Elan Pharmaceuticals, Janssen Alzheimer Immunotherapy and Pfizer.

Similarly, a second presentation showed that a compound known as AN1792 (made by Elan), by attacking beta amyloid plaques, also was associated with reductions in tau levels.

This trial involved continued follow-up on 10 patients involved in a trial that was halted in 2002 after some participants developed symptoms of brain inflammation.

All 10 patients had been immunized with AN1792. They were compared with 28 Alzheimer's patients who had not been immunized.

And finally, two other animal studies looked at immunization targeted directly at the tau protein.

One found that "passive immunization" with a compound known as the PHF1 antibody not only decreased tau levels but also symptoms in mice.

The study was partially supported by Applied Neurosolutions Inc. and the Alzheimer's Association.

And a group of European researchers reported developing a new rat model that enables researchers to study tau neurofibrillary tangles.

When immunized with an early version of a tau vaccine, the rats showed decreases in tau tangles with associated improvements in functioning, the researchers said.

But again, Kennedy cautioned that the promise from this type of research may still not pan out.

While he believes that this type of study should be pursued, "a lot of us think that both beta amyloid and tau are a blind alley, that something farther upstream may be causing Alzheimer's," Kennedy said.

There is another problem with the approach, though, in that humans make amyloid and tau normally. "Immunizing against naturally occurring natural constituents of the brain, it is a risk," Kennedy said.

More information

There's much more about Alzheimer's disease at the Alzheimer's Association.

SOURCES: William Thies, Ph.D., chief medical and scientific officer, Alzheimer's Association; Gary Kennedy, M.D., director of geriatric psychiatry, Montefiore Medical Center, New York, N.Y.; July 13, 2010, presentations, International Conference on Alzheimer's Disease 2010, Honolulu


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Embedded Mobile & M2M Device revenues to Rise to Almost $19 Billion Globally by 2014, Says Juniper Research
2. 2010 HSR Impact Award recognizes surgical safety research
3. MSU launches first anti-counterfeiting research program
4. Researchers map all the fragile sites of the yeast Saccharomyces cerevisiaes genome
5. UH Case Medical Center researchers publish promising findings for advanced cervical cancer
6. Researchers discover new way to kill pediatric brain tumors
7. Family Research Council: Planned Parenthood Report Oversexualizes Ten-Year-Olds, Undermines Parental Authority
8. Michael J. Fox Foundation Awards $1 Million to Drive Critical New Research Tools and Technologies in Parkinsons Drug Development
9. Luth Researchs IndicatorEDG(TM) Study Finds Americans Hopes of Achieving Their Dreams Are Fading
10. International Diabetes Federation awards $2 million to 9 global diabetes research projects
11. Gladstones Robert Mahley to receive Research!America advocacy award
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Alzheimer's Research Spotlights Protein 'Tangles' in Brain
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding ... of its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. ... James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of ... of the latter, setting the bar too high can result in disappointment, perhaps even ... progress toward their goal. , Research from PsychTests.com reveals that behind ...
(Date:6/24/2016)... ... ... was in a crisis. Her son James, eight, was out of control. Prone to extreme ... “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was ... other children and say he was going to kill them. If we were driving ...
(Date:6/24/2016)... ... 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited to ... Recovery® program to drive cancer patients to and from their cancer treatments. Comfort ... quality of life and ongoing independence. Getting to and from medical treatments is ...
(Date:6/24/2016)... ... 24, 2016 , ... The Haute Beauty Network, affiliated with ... as a prominent plastic surgeon and the network’s newest partner. , Dr. ... handsome men, look naturally attractive. Plastic surgery should be invisible.” He stands by ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the addition of ... report to their offering. ... kidney failure, it replaces the function of kidneys by removing ... thus the treatment helps to keep the patient body,s electrolytes ... Increasing number of ESRD patients & substantial healthcare expenditure ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... - Forecast to 2022" report to their offering. ... to date financial data derived from varied research sources to ... potential impact on the market during the next five years, ... of sub markets, regional and country level analysis. The report ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 /PRNewswire/ ... Diabetes Tomorrow,s Leaders Scholarship is any indication, the future ... today online at www.diabetesscholars.org by the Diabetes ... stand in the way of academic and community service ... scholarship program since 2012, and continues to advocate for ...
Breaking Medicine Technology: